ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1115

Medication Co-pay Modifies Treatment Adherence in Patients with Systemic Lupus Erythematosus

Raisa Lomanto Silva1, Gretchen M Swabe2 and Jared W Magnani3, 1University of Pittsburgh Medical Center, Pittsburgh, PA, 2Division of Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 3Heart and Vascular Institute, University of Pittsburgh Medical Center; Division of Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, PA

Meeting: ACR Convergence 2022

Keywords: socioeconomic factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Plenary II

Session Type: Plenary Session

Session Time: 11:30AM-1:00PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with significant morbidity and mortality. Adherence to SLE medications is challenging and estimated as 30-80% for prescribed therapies. Hydroxychloroquine, the backbone of SLE treatment, has been associated with very poor adherence. Multiple social factors may affect treatment adherence. The costs of insurance copayment, or copays, may represent a major obstacle to adherence, particularly for individuals with limited social resources. We investigate the association between SLE medications co-pay and adherence.

Methods: We used an administrative claims dataset (Optum’s de-identified Clinformatics® Data Mart Database) to identify individuals with incident SLE diagnosis (defined as 2 ICD-9/10 codes within 30 days) between 2010-19 receiving hydroxychloroquine (HCQ), azathioprine (AZA), or mycophenolate mofetil (MMF) and at least 90 days of medication claims data. We dichotomized copays into low (<$10/30 days) and high (≥$10/30 days). We examined the association between medication copay and odds of adherence in multivariable-adjusted regression models. Adherence was defined as proportion of days covered (PDC) ≥80%. We adjusted for demographics, comorbid conditions, and socioeconomic factors including annual household income and educational attainment.

Results: We identified 12510 individuals (age 54.2±15.5; 88.2% women; 14.9% Black race), of whom 9510 (76%) were on HCQ and 15% on HCQ and another medication. Median (IQR) 30-day copays were $8 (4, 10) for HCQ, $7 (2, 10) for AZA, and $10 (5, 20) for MMF. We identified significant associations between higher copays and lower adherence. In our fully adjusted model, high copays were associated with 39% (95% CI, 0.55-0.68) lower odds of adherence for HCQ; 56% (95% CI, 0.29-0.65) lower odds of adherence for AZA; and 32% (95% CI 0.49-0.96) lower odds of adherence for MMF.

Conclusion: In a large, administrative health claims database we identified that increased copays are associated with reduced adherence to the most commonly used medications for SLE. Incorporating awareness of the burden of copayments and their consequences into health care practice is essential for improving medication access in individuals with this complex condition.

Supporting image 1

Graph 1. Odds Ratio of Adherence by Medication Class adjusted for Demographics and Socioeconomic Factors

Supporting image 2

Graph 2. Copay and Adherence (Proportion of Days Covered) per Medication Class


Disclosures: R. Lomanto Silva, None; G. M Swabe, None; J. W Magnani, None.

To cite this abstract in AMA style:

Lomanto Silva R, M Swabe G, W Magnani J. Medication Co-pay Modifies Treatment Adherence in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/medication-co-pay-modifies-treatment-adherence-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/medication-co-pay-modifies-treatment-adherence-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology